Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Lurbinectedin in PARP resistant breast cancer

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.10.16
Views: 2715

Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Dr Cruz speaks with ecancer at ESMO 2016 about trials for lurbinectedin in patients for whom PARP inhibition is no longer and option.

She describes the mechanisms by which resistance to other medications can be subverted by lurbinectedin, and reports its suitability even for tumours with resistance to standard therapy cisplatin.

Lurbinectedin is discussed further by Dr Judith Balmaña, who spoke with ecancer here.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation